Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kailera TherapeuticsKLRA -0.23%12 PB Ratio is 1.49 as of Sep. 18, 2026. GuruFocus rates KLRA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,223 Biotechnology companies, Kailera Therapeutics ranks better than 72.61% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Kailera Therapeutics PB Ratio Related Terms
Kailera Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Kailera Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kailera Therapeutics PB Ratio Chart
Kailera Therapeutics Annual Data
Trend
Dec24
Dec25
PB Ratio
0.00
0.00
Kailera Therapeutics Quarterly Data
Jun25
Mar26
Jun26
PB Ratio
0.00
0.00
2.55
KLRA vs VCEL, ADMA, COAG: PB Ratio Comparison
For the Biotechnology subindustry, Kailera Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kailera Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kailera Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Kailera Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Kailera Therapeutics (KLRA) has a PB Ratio of 1.49 as of Sep. 18, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kailera Therapeutics and its competitors. According to the industry distribution chart, Kailera Therapeutics ranks #335 out of 1223 companies in the Biotechnology industry, placing it in the top 27.4%.
Is Kailera Therapeutics' PB Ratio too high?
Kailera Therapeutics' current PB Ratio is 1.49. The Biotechnology industry median PB Ratio is 2.91. Kailera Therapeutics' value of 1.49 is 48.8% below this industry median. Based on the distribution chart, Kailera Therapeutics ranks #335 out of 1223 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Kailera Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kailera Therapeutics' PB Ratio compare to VCEL and ADMA?
According to the Biotechnology industry distribution chart, Kailera Therapeutics ranks #335 out of 1223 companies for PB Ratio. This puts Kailera Therapeutics in the upper half of its industry. The industry median PB Ratio is 2.91. Kailera Therapeutics' value of 1.49 is 48.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.91, based on 1,223 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kailera Therapeutics's current PB Ratio of 1.49 is 48.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kailera Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kailera Therapeutics's current PB Ratio is 1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kailera Therapeutics stock overvalued right now?
Kailera Therapeutics (KLRA) has a current PB Ratio of 1.49. The current PB Ratio is 1.49 and 48.8% below the Biotechnology industry median of 2.91. Kailera Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Kailera Therapeutics (KLRA), the current PB Ratio is 1.49 as of Sep. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
12GF Score
Get the complete analysis for KLRA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KLRA has been successfully added to your 
